InvestWiser

BioPorto

BIOPORNasdaq CopenhagenHealthcareMarket value 470 m DKK
0.95DKK −2.6%
last day · Price as of 19 November 2026

The answer first

Does BioPorto beat the market?

No, BioPorto has not beaten the market over the last year.

BioPorto−11.2%København (OMXCGI)+13.9%
  • The ranking · Quality, value and trend combined

    Better than 29% of Nordic stocks

    • Quality93
    • Value8
    • Trend22

    No. 107 of 195 in healthcare

Max for seven days

Follow BioPorto with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on BioPorto

From today, at a price of 0.95 DKK. Write why you follow BioPorto, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about BioPorto

Your first answer is free, no account needed.

Do you own BioPorto, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with BioPorto and a few more. Free, no card.

Past year against the exchange and Super Stock
BioPorto−11.2%København (OMXCGI)+13.9%Super Stock+44.6%
17 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • BioPorto has fallen 11.2% over the past year, including dividends.
  • Overall, BioPorto ranks better than 29% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 75.9%. The price is 99.5% below its peak now.

What do analysts think of BioPorto?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

29

Quality, value and trend together. Better than 29% of Nordic stocks.

No. 107 of 195 in healthcare

Quality93
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 24 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.13
  • Asset turnoverSales divided by everything the company owns0.34
  • Return on equityProfit divided by equity+10.5%
  • Cash conversionOperating cash flow divided by profit−8.40

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value8
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 145 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity5.5
  • P/SPrice divided by sales12.2
  • P/EPrice divided by earnings52.2
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend22
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 118 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−24.7%
  • 6 months−22.9%
  • 9 months−1.2%
  • 12 months−11.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−8.2%
3 years, per year
−19.1%
5 years, per year
−21.0%
10 years, per year
−5.0%
Largest fall, 3 years
−75.9%
From a peak to the bottom
From the peak now
−99.5%
How far the price is from the peak
Volatility, 1 year
49.2%
How much the price swings over a year
Beta, 1 year
0.52
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own BioPorto

4 funds we follow own BioPorto. The share is how much of the fund the stock makes up.

  • Denmark4

From the funds' latest known holdings.

About BioPorto

BioPorto is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 44 employees.

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabe…

See the full analysis of BioPorto.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Copenhagen

Explore the stock market